Wall Street Zen Upgrades Maze Therapeutics (NASDAQ:MAZE) to “Hold”

Maze Therapeutics (NASDAQ:MAZE) was upgraded by stock analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued to investors on Saturday.

Several other analysts have also issued reports on the company. Lifesci Capital upgraded Maze Therapeutics to a “strong-buy” rating in a report on Thursday, December 18th. Mizuho upgraded Maze Therapeutics to a “strong-buy” rating in a research note on Wednesday, March 11th. Wedbush raised their price target on Maze Therapeutics from $43.00 to $58.00 and gave the stock an “outperform” rating in a research note on Monday, March 16th. Truist Financial started coverage on Maze Therapeutics in a report on Tuesday, March 17th. They set a “buy” rating and a $68.00 price target for the company. Finally, Wells Fargo & Company assumed coverage on Maze Therapeutics in a research note on Thursday, December 4th. They issued an “overweight” rating and a $55.00 price target for the company. Three analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, Maze Therapeutics currently has an average rating of “Buy” and an average price target of $64.11.

Maze Therapeutics Stock Performance

Shares of MAZE opened at $30.38 on Friday. The company has a market capitalization of $1.51 billion, a PE ratio of -9.41 and a beta of 4.46. The company’s 50 day moving average price is $45.61 and its 200 day moving average price is $37.92. Maze Therapeutics has a 52 week low of $6.71 and a 52 week high of $53.65.

Maze Therapeutics (NASDAQ:MAZE) last released its earnings results on Wednesday, March 25th. The company reported ($0.65) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.73) by $0.08.

Insider Buying and Selling

In related news, CMO Harold Bernstein sold 15,000 shares of the company’s stock in a transaction on Friday, March 20th. The shares were sold at an average price of $49.10, for a total value of $736,500.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Atul Dandekar sold 7,500 shares of the stock in a transaction on Thursday, January 29th. The stock was sold at an average price of $44.27, for a total transaction of $332,025.00. Following the transaction, the insider directly owned 10,503 shares in the company, valued at $464,967.81. The trade was a 41.66% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 117,600 shares of company stock worth $5,337,248.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the stock. Royal Bank of Canada lifted its holdings in Maze Therapeutics by 128.3% in the 4th quarter. Royal Bank of Canada now owns 646 shares of the company’s stock worth $27,000 after purchasing an additional 363 shares during the last quarter. GF Fund Management CO. LTD. bought a new position in shares of Maze Therapeutics in the fourth quarter valued at approximately $39,000. Caitong International Asset Management Co. Ltd bought a new position in shares of Maze Therapeutics in the fourth quarter valued at approximately $43,000. California State Teachers Retirement System lifted its stake in shares of Maze Therapeutics by 138.0% in the fourth quarter. California State Teachers Retirement System now owns 1,321 shares of the company’s stock worth $55,000 after buying an additional 766 shares during the last quarter. Finally, Ameritas Investment Partners Inc. boosted its holdings in shares of Maze Therapeutics by 82.6% during the 3rd quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock worth $42,000 after buying an additional 738 shares during the period.

Trending Headlines about Maze Therapeutics

Here are the key news stories impacting Maze Therapeutics this week:

• Positive Sentiment: HC Wainwright materially raised near‑term EPS estimates across 2026–2029 and boosted FY2030 to $1.00 while maintaining a “Buy” rating and a $110 price target — a strong analyst endorsement that supports upside if development and regulatory paths stay on track. HC Wainwright Boosts Maze Therapeutics (NASDAQ:MAZE) Price Target to $110.00
• Positive Sentiment: BTIG issued a “Buy” rating, adding further sell‑side support that could attract buyers looking for durable conviction from institutional analysts. Maze Therapeutics (NASDAQ:MAZE) Earns “Buy” Rating from BTIG Research
• Positive Sentiment: Phase 2 HORIZON data for MZE829 showed a clinically meaningful ~35.6% mean reduction in proteinuria (uACR), exceeding the ≥30% threshold cited for regulatory relevance — the fundamental clinical readout supports a pathway toward a pivotal trial. Maze Therapeutics: MZE829 Presses Forward Despite Stock Price Drop
• Neutral Sentiment: Technical metrics show the stock moved into oversold territory after the selloff, and some analysts/technicals argue the decline may have exhausted short‑term sellers — this could set up a technical bounce independent of fundamentals. After Plunging 30.8% in 4 Weeks, Here’s Why the Trend Might Reverse for Maze Therapeutics
• Negative Sentiment: Despite positive efficacy, the market treated the Phase 2 results as “mixed” on endpoints/subgroup/readout detail, triggering a steep selloff that wiped nearly a third of market value — heightened volatility and investor uncertainty remain key near‑term risks. Maze Loses Nearly a Third of Market Cap on Mixed Midstage Kidney Drug Data
• Negative Sentiment: A shareholder law firm (Johnson Fistel) has opened an investigation into potential claims related to MAZE disclosures — this introduces legal/PR risk and could prolong downward pressure if it results in litigation or heightened scrutiny. MAZE Shareholders Are Encouraged to Reach Out to Johnson Fistel
• Negative Sentiment: Media coverage captured the paradox of “best‑in‑class potential” commentary alongside a sharp post‑readout plunge, amplifying sentiment swings and increasing short‑term trading risk. After ph. 2 readout, analysts herald best‑in‑class potential as stock plummets

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.